Alternative splicing Lung cancer Bcl-x, CD44 RNA binding protein hnRNP
Fecha de publicación:
Lippincott, Williams & Wilkins
Pio R, Montuenga LM. Alternative splicing in lung cancer. J Thorac Oncol 2009 Jun;4(6):674-678.
Abstract: Alterations in alternative splicing affect essential biologic
processes and are the basis for a number of pathologic conditions,
including cancer. In this review we will summarize the evidence
supporting the relevance of alternative splicing in lung cancer. An
example that illustrates this relevance is the altered balance between
Bcl-xL and Bcl-xS, two splice variants of the apoptosis regulator
Bcl-x. Splice modifications in cancer-related genes can be associated
with modifications either in cis-acting splicing regulatory sequences
or in trans-acting splicing factors. In fact, lung tumors show abnormal
expression of splicing regulators such as ASF/SF2 or some
members of the heterogeneous nuclear ribonucleoprotein family.
The potential significance of alternative splicing as a target for lung
cancer diagnosis or treatment will also be discussed.